Human Bladder Cancer Tissue Lysates

Pricing
Normal Lysates: $125.00/100 ug
Tumor Lysates: $175.00/100 ug
Nor./Tum. set: $270.00 (10% off)
Discounts
2-8    Vials  10%
9-20  Vials  15%
>20   Vials   20%

Call, Fax, or Email Your Order!

Introduction:

Histologic types of urinary bladder cancer include the following:

More than 90% of bladder carcinomas are transitional cell carcinomas derived from the uroepithelium. About 6% to 8% are squamous cell carcinomas and 2% are adenocarcinomas. Adenocarcinomas may be either of urachal origin or of nonurachal origin; the latter type is generally thought to arise from metaplasia of chronically irritated transitional epithelium. Pathologic grade, which is based on cellular atypia, nuclear abnormalities, and the number of mitotic figures is of great prognostic importance.

Human Bladder Cancer Lysates

Catalog Number

Diagnosis

Grade

Stage

TNM

Sex

Age

T10-001

Transitional cell carcinoma

n/a

I

T1bNxM0

F

57

T10-002

Papillary transitional cell carcinoma

1

II

T2NxM0

M

56

T10-003

Transitional cell carcinoma

2

II

T2NxM0

M

64

T10-004

Epidermoid carcinoma

2

III

T3N0M0

M

71

T10-005

Papillary transitional cell carcinoma

n/a

n/a

n/a

M

52

T10-006

Transitional cell carcinoma

1

II

T2bN0M0

M

42

T10-007

Squamous cell carcinoma

2

III

T3NxM0

M

39

T10-008

Transitional cell carcinoma

1

III

T3NxM0

F

45

T10-009

Transitional cell carcinoma

2

II

T2bmN0M0

F

52

T10-010

Transitional cell carcinoma

3

II

T2bNxM0

M

70

T10-011

Squamous cell carcinoma

3

II

T2NxM0

M

54

T10-012

Squamous cell carcinoma

2

II

T2bNxM0

M

62

T10-013

Adenocarcinoma

3

II

T2mNxM0

M

74

T10-014

Transitional cell carcinoma

2

II

T2NxM0

M

39

T10-015

Transitional cell carcinoma

n/a

II

T2bNxM0

M

57

T10-016

Transitional cell carcinoma, moderately differentiated.

2

n/a

n/a

M

74

T10-017

Transitional cell carcinoma, moderately differentiated.

2

n/a

n/a

F

85

T10-018

Transitional cell carcinoma, moderately differentiated.

2

n/a

n/a

M

76

T10-019

Transitional cell carcinoma, poorly differentiated.

3

n/a

n/a

M

70

T10-020

Transitional cell carcinoma, moderately differentiated.

2

n/a

n/a

M

39

T10-021

Transitional cell carcinoma, moderately differentiated.

2

n/a

n/a

M

29

T10-022

Transitional cell carcinoma, poorly differentiated.

3

n/a

T3bNxMx

M

70

T10-023

Adenocarcinoma, moderately differentiated.

2

n/a

n/a

M

43

T10-024

Transitional cell carcinoma, poorly differentiated.

3

n/a

n/a

M

62

T10-025

Transitional cell carcinoma, poorly differentiated.

3

n/a

n/a

M

62

T10-026

Transitional cell carcinoma, moderately differentiated.

3

n/a

n/a

M

63

T10-027

Transitional cell carcinoma, poorly differentiated.

3

n/a

n/a

M

39

T10-028

Transitional cell carcinoma, poorly differentiated.

3

n/a

n/a

M

75

T10-029

Transitional cell carcinoma, well differentiated.

1

n/a

n/a

M

71

T10-030

Adenocarcinoma, poorly differentiated.

3

n/a

n/a

M

67

 

References:

Mostofi FK, Davis CJ, Sesterhenn IA: Pathology of tumors of the urinary tract. In: Skinner DG, Lieskovsky G, eds.: Diagnosis and Management of Genitourinary Cancer. Philadelphia, Pa: WB Saunders, 1988., pp 83-117.

Wilson TG, Pritchett TR, Lieskovsky G, et al.: Primary adenocarcinoma of bladder. Urology 38 (3): 223-6, 1991.

LiVolsi VA: Pathology of thyroid disease. In: Falk SA: Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. Philadelphia, PA: Lippincott-Raven, 1997., pp 127-175.